{"id":242035,"date":"2012-09-12T16:15:55","date_gmt":"2012-09-12T16:15:55","guid":{"rendered":"http:\/\/www.eugenesis.com\/acceleron-founder-dr-tom-maniatis-to-receive-the-2012-lasker-award-in-medical-science\/"},"modified":"2012-09-12T16:15:55","modified_gmt":"2012-09-12T16:15:55","slug":"acceleron-founder-dr-tom-maniatis-to-receive-the-2012-lasker-award-in-medical-science","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biochemistry\/acceleron-founder-dr-tom-maniatis-to-receive-the-2012-lasker-award-in-medical-science.php","title":{"rendered":"Acceleron Founder Dr. Tom Maniatis To Receive The 2012 Lasker Award in Medical Science"},"content":{"rendered":"<p><p>    CAMBRIDGE, Mass.--(BUSINESS WIRE)--  <\/p>\n<p>    Acceleron Pharma, Inc., a biopharmaceutical company developing    protein therapeutics for cancer and orphan diseases, announced    that Tom Maniatis, Ph.D., an Acceleron co-founder and Professor    and Chair of the Department of Biochemistry and Molecular    Biophysics at the Columbia University College of Physicians and    Surgeons, is to be honored with the 2012 Lasker-Koshland    Special Achievement Award in Medical Science. The Albert and    Mary Lasker foundation award is considered to be one of the    most prestigious scientific prizes and the Special Achievement    Award recognizes its recipients for exceptional leadership and    citizenship in biomedical science. Dr. Maniatis will be    presented with the Lasker-Koshland Special Achievement Award in    Medical Science on September 21st in New York City.  <\/p>\n<p>    Dr. Maniatis is a pioneer in the development of gene cloning    technology, and he has published extensively in the field of    eukaryotic gene regulation. In particular, he identified    numerous genetic defects that underlie the inherited human    illness -thalassemia. Dr. Maniatis is widely known for his    seminal work developing gene cloning technologies and applying    those methods to discovering the genetic bases of human    diseases. His book, The Cloning Manual, has become a    world-wide resource.  <\/p>\n<p>    In addition to these scientific accomplishments, Dr. Maniatis    has been instrumental in creating successful biotechnology    companies. He was a co-founder of Genetics Institute, where he    chaired the scientific board and served on the board of    directors for more than 17 years. During this time, Genetic    Institutes gained FDA approval for several protein-based    drugs, including recombinant human erythropoietin, Factor VIII    and Factor IX, as well as bone morphogenic proteins. Dr.    Maniatis was also a co-founder of ProScript Inc., which    discovered the drug Velcade (bortezomib). Dr.    Maniatis is currently a member of the board of directors at    Acceleron.  <\/p>\n<p>    Mark Ptashne, Ph.D., the Ludwig Chair of Molecular Biology at    Memorial Sloan-Kettering Cancer Center in New York, a    co-founder of Genetics Institute and Acceleron, and a previous    Lasker awardee said, Ive worked with Tom for many years in    both basic science and biotechnology,he is simply the best.  <\/p>\n<p>    Tom has had an enormous impact on the scientific community and    an equally impressive contribution to the discovery and    development of innovative medicines at several biotechnology    companies, said John Knopf, Ph.D., Chief Executive Officer of    Acceleron. I have had the distinct pleasure of knowing and    working with Tom since I joined Genetics Institute 30 years    ago. I personally continue to benefit significantly from his    involvement at Acceleron as does our entire team of world-class    scientists.  <\/p>\n<p>    About Acceleron  <\/p>\n<p>    Acceleron is a privately-held biopharmaceutical company    committed to discover, develop, manufacture and commercialize    novel protein therapeutics for orphan diseases and cancer.    Accelerons scientific approach takes advantage of its unique    insight to discover first-in-class therapies based on the TGF-    protein superfamily. Acceleron utilizes proven biotherapeutic    technologies and capitalizes on the companys internal GMP    manufacturing capability to advance its therapeutic programs    rapidly and efficiently. The investors in Acceleron include    Advanced Technology Ventures, Alkermes, Avalon Ventures,    Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities,    OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill    Ventures and Venrock. For further information on Acceleron,    please visit     <a href=\"http:\/\/www.acceleronpharma.com\" rel=\"nofollow\">http:\/\/www.acceleronpharma.com<\/a>.  <\/p>\n<\/p>\n<p>Continue reading here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/acceleron-founder-dr-tom-maniatis-130000773.html;_ylt=A2KJ3CUntVBQPzEAFI3_wgt.\" title=\"Acceleron Founder Dr. Tom Maniatis To Receive The 2012 Lasker Award in Medical Science\">Acceleron Founder Dr. Tom Maniatis To Receive The 2012 Lasker Award in Medical Science<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced that Tom Maniatis, Ph.D., an Acceleron co-founder and Professor and Chair of the Department of Biochemistry and Molecular Biophysics at the Columbia University College of Physicians and Surgeons, is to be honored with the 2012 Lasker-Koshland Special Achievement Award in Medical Science.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biochemistry\/acceleron-founder-dr-tom-maniatis-to-receive-the-2012-lasker-award-in-medical-science.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577469],"tags":[],"class_list":["post-242035","post","type-post","status-publish","format-standard","hentry","category-biochemistry"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/242035"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=242035"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/242035\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=242035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=242035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=242035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}